• 1
    The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensives patients randomized to angiotensin-converting enzymes inhibitor or calcium-channel blocker versus diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 29812997.
  • 2
    Bakris G, Hill M, Mancia G, et al. Achieving blood pressure control goals globally: five core actions for health-care professionals. A world-wide call to action. J Hum Hypertens. 2008;22:6370.
  • 3
    Berlowitz DR, Aash AS, Hickey EC, et al. Infrequent management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 4
    Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organization. J Manag Care Pharm. 2006;12:239245.
  • 5
    Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002;288(15):19091914.
  • 6
    Carter BL, Zillich AJ, Elliott WJ. How pharmacists can assist physicians with controlling BP. J Clin Hypertens. 2003;5:3137.
  • 7
    Cherry SB, Benner JS, Hussein Ma, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12:489497.
  • 8
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:12061252.
  • 9
    Cooper LA. A 41-year-old African American man with poorly controlled hypertension: review of patient and physician factors related to hypertension treatment adherence. JAMA. 2009;301(12):12601272.
  • 10
    Curzio JL, Beevers M. The role of nurses in hypertension care and research. J Hum Hypertens. 1997;11:541550.
  • 11
    Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment and control rates in the United States adults between 1988–1994 and 1999–2004. Hypertension. 2008;52:818827.
  • 12
    Dennison C, Post WS, Kim MT, et al. Underserved urban African American men: hypertension trial outcomes and mortality during 5 years. Am J Hypertens. 2007;20:164171.
  • 13
    DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794811.
  • 14
    Dunbar-Jacobs J, Dwyer K, Dunning R. Compliance with antihypertensive regimen: a review of the research in the 1980s. Ann Behav Med. 1991;3:3139.
  • 15
    Hill MN. Strategies for patient education. Clinical Exp Hypertens. 1989;11:11871201.
  • 16
    Foody J. Medication adherence: America’s other drug problem. Available at:
  • 17
    Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and SBP control. Clin Ther. 2007;29:972984.
  • 18
    HaynesRB, TaylorDW, SackertDL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press; 1979.
  • 19
    Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008; (2):CD000011. Brief record.
  • 20
    Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:25622571.
  • 21
    Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the Hypertension Detection and Follow-up Program. II. Mortality by race-sex and age. JAMA. 1979;242:25722577.
  • 22
    Heisler M, Wagner TH, Piette JD. Patient strategies to cope with high prescription medication costs: who is cutting back on necessities, increasing debt, or underusing medications? J Behav Med. 2005;28:4351.
  • 23
    Hill MN, Bone LR, Levine DM. Community outreach. In: OparilS, WeberM, eds. Hypertension, 2nd edn. Philadelphia, PA: Elsevier Saunders; 2005:423429.
  • 24
    Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479486.
  • 25
    Hyman DJ, Pavlik VN. Poor hypertension control: let’s stop blaming patients. Cleve Clin J Med. 2002;69:793799.
  • 26
    Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15:9096.
  • 27
    Kripalani Yao X, Haynes B. Interventions to enhance medication adherence in chronic medical conditions. A systematic review. Arch Intern Med. 2007;167:540550.
  • 28
    McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):26352645.
  • 29
    McLeroy KR, Bibeau D, Steckler A, et al. An ecological perspective on health promotion programs. Health Educ Q. 1988;15:351377.
  • 30
    Milchak JL, Carter BL, Ardery G, et al. Development of explicit criteria to measure adherence to hypertension guidelines. J Hum Hypertens. 2006;20:426433.
  • 31
    Milchak JL, Carter BL, James PA, et al. Physician adherence to JNC 7 guidelines and blood pressure control. Am J Hypertens. 2005;18:190A190A.
  • 32
    Miller NH, Hill MN, Kottke T, et al. The multilevel compliance challenge: Recommendations for a call to action. Circulation. 1997;95:10851090.
  • 33
    Miller NH, Hill MN. Non-physician providers and the Management of Hypertension. In: IzzoJL, BlackHR, eds. Hypertension Primer, 3rd ed. Dallas, TX: American Heart Association; 2003:399401.
  • 34
    Miller NH, Hill MN. Nursing clinics in the management of hypertension. In OparilS, WeberM, eds. Hypertension, 2nd edn. Philadephia, PA: Elsevier Saunders; 2005:416422.
  • 35
    Miller WR, Rollnick S. Motivational Interviewing Preparing People for Change, 2nd edn. New York, NY: The Guilford Press; 2002.
  • 36
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:6774.
  • 37
    Moser M, Franklin SS. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens. 2007;5:316323.
  • 38
    Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA. 1982;248:14651477.
  • 39
    Ockene IS, Hebert JR, Ockene JK, et al. Effect of training and a structured office practice on physician-delivered nutrition counseling: the Worcester-Area trial for counseling on hyperlipidemia (WATCH). Am J Prev Med. 1996;12:252258.
  • 40
    Ockene IS, Hayman LL, Pasternack RC, et al. Task force #4 – adherence issues and behavior changes: achieving a long-term solution. 33rd Bethesda Conference. J Am Coll Cardiol. 2002;40(4):630640.
  • 41
    Oliveria SA, Chen RS, McCarthy BD, et al. Hypertension knowledge, awareness, and attitudes in a hypertension population. J Gen Intern Med. 2005;20(3):219225.
  • 42
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487497.
  • 43
    Pickering TP, Houston Miller N, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring. A joint statement by the American Heart Association, American Diabetes Association, and the Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:19.
  • 44
    Piette JD, Heisler M, Horne R, et al. A conceptually based approach to understanding chronically ill patients’ response to medication cost pressures. Soc Sci Med. 2006;62:846857.
  • 45
    Piette JD, Heisler M, Krein S, et al. The role of the patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med. 2005;165:17491755.
  • 46
    Roccella EJ. The National High Blood Pressure Education Program. In: OparilS, WeberM, eds. Hypertension, 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005:715.
  • 47
    Rose AJ, Berlowitz DR, Orner MB, et al. Understanding uncontrolled hypertension: is it the patient or provider? J Clin Hypertens. 2007;12:937943.
  • 48
    Dennison CR, Miller NH. Adherence to antihypertensive therapy. In: IzzoJL, SicaDA, BlackHR, eds. Hypertension Primer: The Essentials of High Blood Pressure, 4th ed. Pennsylvania: Lippincott Williams & Wilkins: 2008:413417.
  • 49
    Sabate E, et al. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
  • 50
    Schedlbauer A, Prasad V, Mulvaney C, et al. What evidence supports the use of computerized alerts and prompts to improve clinicians’ prescribing behavior? J Am Med Inform Assoc. 2009;16(4):531538. Epub 2009 Apr 23.
  • 51
    Schoen C, Osborn R, Doty MM, et al. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff (Millwood). 2009;28(6):w1171w1173. Epub 2009 Nov 2.
  • 52
    Fahey T, Schroeder K, Ebrahim S. Interventions used to improve blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2006;(2):CD005182. Review.
  • 53
    Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004; (2):CD004804. Review
  • 54
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:32553264.
  • 55
    Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension. 2002;40:464469.
  • 56
    Stewart M, Brown JB, Boon H, et al. Evidence on patient-doctor communication. Cancer Prev Control. 1999;3:2530.
  • 57
    The Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267:12131220.
  • 58
    Urquhart J. The odds of the three nons when an aptly prescribed medicine isn’t working: noncompliance, non-absorption, non-response. Br J Clin Pharmacol. 2002;54:212220.
  • 59
    Vawter L, Tong X, Gemilyan M, et al. Barriers to antihypertensive medication adherence among adults – United States, 2005. J Clin Hypertens (Greenwich). 2008;10(12):922929.
  • 60
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202(11):10281034.
  • 61
    Vrijens B, Vincze G, Kristano P, et al. Adherence to prescribed anti-hypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:11141117.
  • 62
    Wagner TH, Heisler M, Piette JD. Prescription drug co-payments and cost-related medication underuse. Health Econ Policy Law. 2008;3:5167.
  • 63
    Wagner EH, Davis C, Schaefer J, et al. A survey of leading chronic disease management programs: are they consistent with the literature? Manag Care Q. 1999;7(3):5666.
  • 64
    Wetzels GE, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens. 2004;10:18491855.
  • 65
    Working Group to Define Critical Patient Behaviors in High Blood Pressure Control (National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute). Patient behavior for blood pressure control. JAMA. 1979;241(23):25342537.
  • 66
    Zolnierek KB, DiMatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826834.